Novavax Inc - NVAX STOCK NEWS

Novavax is set to host a live Q&A conference call on November 10, 2020, due to technical difficulties during its quarterly earnings call on November 9. The session invites the investment community to discuss the Company's third-quarter financial and operational results. The call will commence at 4:30 p.m. ET, following the close of U.S. financial markets, with details available on Novavax's website. A replay will be accessible until November 17, 2020.

Novavax (NVAX) reported a net loss of $197.3 million for Q3 2020, significantly higher than the $18 million loss in Q3 2019. Revenue reached $157 million, boosted by funding for NVX-CoV2373, its COVID-19 vaccine candidate, which has entered a Phase 3 trial in the U.K. with 15,000 participants. The company secured over $2 billion in funding from various sources for clinical development. Manufacturing capacity for NVX-CoV2373 is set to exceed two billion doses by mid-2021. Novavax is also advancing its NanoFlu program with a new leadership team.

Novavax, a late-stage biotechnology firm, has announced leadership changes aimed at enhancing its commercialization strategy. Gregory F. Covino joins as CFO, bringing extensive global financial expertise. John Trizzino shifts from CFO to Chief Commercial Officer to focus on advancing the COVID-19 vaccine candidate NVX-CoV2373 and NanoFlu. Filip Dubovsky is promoted to Executive Vice President and Chief Medical Officer, while Biegie Lee becomes Senior Vice President and Chief Information Officer.

These changes are crucial as Novavax prepares to enter global markets with its promising vaccine candidates.

Novavax (Nasdaq: NVAX) has received Fast Track Designation from the FDA for its COVID-19 vaccine candidate, NVX-CoV2373. This designation aims to expedite the development and regulatory review process, highlighting the urgent need for an effective vaccine. The Phase 3 clinical trial in the U.S. and Mexico is expected to begin by the end of November 2020, with interim data anticipated from the UK trial in early 2021. Novavax has secured $2 billion in funding for its global vaccine program.

Novavax, a late-stage biotechnology company, signed a non-binding Heads of Terms with the Australian Government to supply 40 million doses of its COVID-19 vaccine candidate, NVX-CoV2373. The arrangement aims to provide access to the vaccine, pending successful Phase 3 trials and approval by the Therapeutic Goods Administration. Initial deliveries are expected in the first half of 2021. Notably, Australia has contributed to clinical trials, enhancing the vaccine's development, while Novavax has secured $2 billion in funding for its global vaccine program.

Novavax, Inc. (NASDAQ: NVAX) has appointed Gregg Alton, J.D., as an independent Director on its Board. Alton, with over 20 years of experience, previously held various leadership roles at Gilead Sciences, including interim CEO. This addition comes at a crucial time as Novavax prepares to launch a Phase 3 trial of its COVID-19 vaccine and advance its NanoFlu vaccine toward FDA registration. Alton's extensive background in commercial operations and public affairs is expected to bolster Novavax's efforts in vaccine commercialization.

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company, will report its Q3 2020 financial and operational results on November 9, 2020, after U.S. market close. The conference call is scheduled for 4:30 p.m. ET on the same day. Interested parties can join via a domestic dial-in number (877) 212-6076 or international number (707) 287-9331, using passcode 8059421. The replay will be available from 7:30 p.m. ET on November 9 until November 16, 2020. Novavax is focused on developing vaccines for infectious diseases, including its COVID-19 vaccine candidate NVX-CoV2373.

Novavax, Inc. (Nasdaq: NVAX) has announced the expansion of its Gaithersburg campus, adding two properties to enhance its capabilities in vaccine research, manufacturing, and business operations. This move supports its ongoing COVID-19 vaccine trials and the development of its influenza vaccine, NanoFlu. The company has secured $2 billion in funding for its vaccine efforts, including $1.6 billion from the U.S. government. The new facilities will include 122,000 square feet for operations and will begin preparations for use in early 2021.

Novavax, Inc. (Nasdaq: NVAX) has enrolled over 5,500 participants in its U.K. Phase 3 clinical trial for NVX-CoV2373, aimed at assessing safety and efficacy against COVID-19. The trial will expand to 15,000 participants, with full enrollment expected by the end of November. Event-driven interim data may be available as early as Q1 2021. A U.S. Phase 3 trial is anticipated to start by the end of November, although it faced some manufacturing delays. Novavax will present new data from its ongoing Phase 1/2 trial during the CDC's ACIP meeting on October 30.